Edgewise Initiates Late-Stage Trial for EDG-7500 Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Source: seekingalpha
- Clinical Trial Progress: Edgewise Therapeutics announced it will initiate a late-stage trial for EDG-7500 later this year, following positive results from the mid-stage CIRRUS-HCM trial, although the stock fell over 10% in premarket trading, indicating market caution regarding the news.
- Safety Assessment: According to topline data from the Phase 2 CIRRUS-HCM trial, EDG-7500 showed no new safety signals and did not affect the heart's systolic function while treating obstructive and nonobstructive forms of HCM, laying a foundation for its future clinical application.
- Cardiac Function Metrics: Among 53 participants, there were no “meaningful” changes in left ventricular ejection fraction (LVEF), with no instances dropping below 50%, suggesting EDG-7500's potential to maintain cardiac function and positively impact patients with hypertrophic cardiomyopathy.
- Future Development Plans: Edgewise plans to start Phase 3 development for EDG-7500 in Q4 2026, with CEO Kevin Koch emphasizing that this research marks an important milestone for both the company and the HCM community, demonstrating EDG-7500's potential to address diastolic dysfunction without significant impact on LVEF.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EWTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EWTX
Wall Street analysts forecast EWTX stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 35.210
Low
16.00
Averages
38.14
High
51.00
Current: 35.210
Low
16.00
Averages
38.14
High
51.00
About EWTX
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Edgewise Initiates Late-Stage Trial for EDG-7500 Treatment
- Clinical Trial Progress: Edgewise Therapeutics announced it will initiate a late-stage trial for EDG-7500 later this year, following positive results from the mid-stage CIRRUS-HCM trial, although the stock fell over 10% in premarket trading, indicating market caution regarding the news.
- Safety Assessment: According to topline data from the Phase 2 CIRRUS-HCM trial, EDG-7500 showed no new safety signals and did not affect the heart's systolic function while treating obstructive and nonobstructive forms of HCM, laying a foundation for its future clinical application.
- Cardiac Function Metrics: Among 53 participants, there were no “meaningful” changes in left ventricular ejection fraction (LVEF), with no instances dropping below 50%, suggesting EDG-7500's potential to maintain cardiac function and positively impact patients with hypertrophic cardiomyopathy.
- Future Development Plans: Edgewise plans to start Phase 3 development for EDG-7500 in Q4 2026, with CEO Kevin Koch emphasizing that this research marks an important milestone for both the company and the HCM community, demonstrating EDG-7500's potential to address diastolic dysfunction without significant impact on LVEF.
See More
Edgewise Therapeutics Reports Positive Phase 2 Results for EDG-7500 in HCM Patients
- Clinical Trial Results: Edgewise Therapeutics announced positive 12-week Phase 2 results for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) patients, with 90% of patients showing significant improvements in hemodynamic measures and 74% achieving normalization or a 50% reduction in NT-proBNP levels.
- Safety Assessment: Among 53 participants, EDG-7500 was generally well tolerated, with nearly all adverse events classified as mild to moderate, and no significant reductions in left ventricular ejection fraction observed, indicating the drug's safety in terms of cardiac function.
- Dose Response: In patients with obstructive HCM, EDG-7500 demonstrated significant reductions in LVOT-G, with 70% of patients showing at least one class improvement in New York Heart Association functional class, highlighting the drug's potential in enhancing cardiac function.
- Future Development Plans: Based on the data from CIRRUS-HCM, Edgewise plans to initiate Phase 3 clinical trials for EDG-7500 in the fourth quarter of 2026, aiming to further validate its therapeutic potential in hypertrophic cardiomyopathy treatment.
See More
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On May 29, 2026, Edgewise Therapeutics granted a total of 74,000 inducement stock options to four new non-executive employees, aimed at attracting talent and strengthening the team.
- Exercise Price Setting: Each inducement stock option has an exercise price of $34.16 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: The vesting schedule for these stock options stipulates that 25% will vest on each employee's one-year anniversary, with the remaining shares vesting monthly, thereby incentivizing continued contributions during employment.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's strategic considerations and commitment to attracting and retaining key talent.
See More
Servier Acquires Edgewise's Muscular Dystrophy Operations
- Significant Deal Size: Servier's acquisition of Edgewise Therapeutics' muscular dystrophy operations for $2.65 billion, including the lead drug Sevasemten, is expected to close in Q3 2026, indicating Servier's strategic expansion in rare neuromuscular disorders.
- Stock Surge: Edgewise Therapeutics (EWTX) shares soared over 20% on Monday, potentially marking the largest single-day gain in six months, reflecting strong market sentiment towards the deal, and if it closes at current levels, it could push the stock to a record high.
- Drug Development Outlook: Sevasemten, an investigational oral therapy designed to protect muscles from contraction-related damage, is currently undergoing pivotal trials for Becker muscular dystrophy and a Phase 2 study for Duchenne muscular dystrophy, addressing a significant unmet need in the market with no approved treatments available.
- Positive Safety Data: The MESA extension study indicates that Sevasemten maintained stable physical function in Becker muscular dystrophy patients for up to 3.5 years, with a favorable cardiac safety profile over 12 months, showing improved cardiac function in some patients, thereby enhancing the drug's market appeal.
See More
Edgewise to Sell Muscle Disease Business for $1.55 Billion
- Significant Transaction Value: Edgewise Therapeutics has entered into an agreement with Servier to sell its muscle disease business for $1.55 billion in upfront cash, with potential milestone payments of up to $1.1 billion, leading to a total potential consideration of $2.65 billion, which will significantly enhance Edgewise's financial flexibility.
- Strategic Focus Shift: Following the transaction, Edgewise will pivot to focus on cardiovascular therapies, developing drugs such as EDG-7500 and EDG-15400, which is expected to accelerate the unlocking of its cardiovascular pipeline's potential and enhance its competitive position in the market.
- Clinical Data Reporting Plans: Edgewise plans to report 12-week data from the CIRRUS-HCM trial in Q2 2026, which will provide critical insights for the further development of its cardiac drugs, thereby advancing its clinical progress.
- Employee Transition Assurance: All Edgewise employees supporting the muscle disease business will receive comparable offers from Servier, ensuring continuity of operations and future commercial execution, reflecting a commitment to talent retention and strategic integration.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Edgewise Initiates Late-Stage Trial for EDG-7500 Treatment
- Clinical Trial Progress: Edgewise Therapeutics announced it will initiate a late-stage trial for EDG-7500 later this year, following positive results from the mid-stage CIRRUS-HCM trial, although the stock fell over 10% in premarket trading, indicating market caution regarding the news.
- Safety Assessment: According to topline data from the Phase 2 CIRRUS-HCM trial, EDG-7500 showed no new safety signals and did not affect the heart's systolic function while treating obstructive and nonobstructive forms of HCM, laying a foundation for its future clinical application.
- Cardiac Function Metrics: Among 53 participants, there were no “meaningful” changes in left ventricular ejection fraction (LVEF), with no instances dropping below 50%, suggesting EDG-7500's potential to maintain cardiac function and positively impact patients with hypertrophic cardiomyopathy.
- Future Development Plans: Edgewise plans to start Phase 3 development for EDG-7500 in Q4 2026, with CEO Kevin Koch emphasizing that this research marks an important milestone for both the company and the HCM community, demonstrating EDG-7500's potential to address diastolic dysfunction without significant impact on LVEF.
See More
Edgewise Therapeutics Reports Positive Phase 2 Results for EDG-7500 in HCM Patients
- Clinical Trial Results: Edgewise Therapeutics announced positive 12-week Phase 2 results for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) patients, with 90% of patients showing significant improvements in hemodynamic measures and 74% achieving normalization or a 50% reduction in NT-proBNP levels.
- Safety Assessment: Among 53 participants, EDG-7500 was generally well tolerated, with nearly all adverse events classified as mild to moderate, and no significant reductions in left ventricular ejection fraction observed, indicating the drug's safety in terms of cardiac function.
- Dose Response: In patients with obstructive HCM, EDG-7500 demonstrated significant reductions in LVOT-G, with 70% of patients showing at least one class improvement in New York Heart Association functional class, highlighting the drug's potential in enhancing cardiac function.
- Future Development Plans: Based on the data from CIRRUS-HCM, Edgewise plans to initiate Phase 3 clinical trials for EDG-7500 in the fourth quarter of 2026, aiming to further validate its therapeutic potential in hypertrophic cardiomyopathy treatment.
See More
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On May 29, 2026, Edgewise Therapeutics granted a total of 74,000 inducement stock options to four new non-executive employees, aimed at attracting talent and strengthening the team.
- Exercise Price Setting: Each inducement stock option has an exercise price of $34.16 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: The vesting schedule for these stock options stipulates that 25% will vest on each employee's one-year anniversary, with the remaining shares vesting monthly, thereby incentivizing continued contributions during employment.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's strategic considerations and commitment to attracting and retaining key talent.
See More
Servier Acquires Edgewise's Muscular Dystrophy Operations
- Significant Deal Size: Servier's acquisition of Edgewise Therapeutics' muscular dystrophy operations for $2.65 billion, including the lead drug Sevasemten, is expected to close in Q3 2026, indicating Servier's strategic expansion in rare neuromuscular disorders.
- Stock Surge: Edgewise Therapeutics (EWTX) shares soared over 20% on Monday, potentially marking the largest single-day gain in six months, reflecting strong market sentiment towards the deal, and if it closes at current levels, it could push the stock to a record high.
- Drug Development Outlook: Sevasemten, an investigational oral therapy designed to protect muscles from contraction-related damage, is currently undergoing pivotal trials for Becker muscular dystrophy and a Phase 2 study for Duchenne muscular dystrophy, addressing a significant unmet need in the market with no approved treatments available.
- Positive Safety Data: The MESA extension study indicates that Sevasemten maintained stable physical function in Becker muscular dystrophy patients for up to 3.5 years, with a favorable cardiac safety profile over 12 months, showing improved cardiac function in some patients, thereby enhancing the drug's market appeal.
See More
Edgewise to Sell Muscle Disease Business for $1.55 Billion
- Significant Transaction Value: Edgewise Therapeutics has entered into an agreement with Servier to sell its muscle disease business for $1.55 billion in upfront cash, with potential milestone payments of up to $1.1 billion, leading to a total potential consideration of $2.65 billion, which will significantly enhance Edgewise's financial flexibility.
- Strategic Focus Shift: Following the transaction, Edgewise will pivot to focus on cardiovascular therapies, developing drugs such as EDG-7500 and EDG-15400, which is expected to accelerate the unlocking of its cardiovascular pipeline's potential and enhance its competitive position in the market.
- Clinical Data Reporting Plans: Edgewise plans to report 12-week data from the CIRRUS-HCM trial in Q2 2026, which will provide critical insights for the further development of its cardiac drugs, thereby advancing its clinical progress.
- Employee Transition Assurance: All Edgewise employees supporting the muscle disease business will receive comparable offers from Servier, ensuring continuity of operations and future commercial execution, reflecting a commitment to talent retention and strategic integration.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
